

Antibody Drug Conjugates Market Size, Share & Trends Analysis Report By Technology (Cleavable Linker, Non-Cleavable Linker, Linkerless), By Applications (Blood Cancer, Breast Cancer, Urothelial Cancer/Bladder Cancer, Others) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2023-2031

Market Report | 2023-04-18 | 0 pages | Straits Research

AVAILABLE LICENSES:

- Single User License \$4500.00
- Global Site License \$5500.00

Report description:

Antibody Drug Conjugates Market Analysis and Insights

The Antibody Drug Conjugates Market size is anticipated to reach USD 6.48 Billion in 2022 and it is projected to reach USD 24.26 Billion by 2031, growing at a CAGR of % during the forecast period.

The Global Antibody Drug Conjugates Market Analysis report covers comprehensive data on emerging trends, market drivers, growth opportunities, and restraints that can change the market dynamics of the industry. It provides an in-depth analysis of the market segments which include types, applications, and competitor analysis.

The Global Antibody Drug Conjugates Market growth, Size report provides a comprehensive analysis of the Pharmaceuticals industry, analyzes and identifies changes in market conditions set to impact future business decisions by analyzing.

Research Methodology

Our research methodology constitutes a mix of secondary & primary research which ideally starts from exhaustive data mining, conducting primary interviews (suppliers/distributors/end-users), and formulating insights, estimates, growth rates accordingly. Final primary validation is a mandate to confirm our research findings with Key Opinion Leaders (KoLs), Industry Experts, Antibody Drug Conjugates Market includes major supplies & Independent Consultants among others.

Global Market Scope and Antibody Drug Conjugates Market

The scope of the report is to provide a 360-degree view of the market outlook by assessing the entire value chain and analyzing the key Antibody Drug Conjugates Market trends from 2024 to 2032 underlying in specific geographies. Qualitative and quantitative aspects are interlinked to provide rationales on market numbers, CAGR, and forecasts.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Antibody Drug Conjugates Market Country Level Analysis

The Global Antibody Drug Conjugates Market Industry Analysis Research Report provides a basic overview of industry dominating market share expected 2024 to 2032. A detailed section on Antibody Drug Conjugates Market share and status of critical industries is included in the report, covering. Market Segment by Regions (North America, Europe, Asia Pacific, South America and The Middle East and Africa), coverage with region wise data from 2024 to 2032.

Top Players in Antibody Drug Conjugates Market

Some of the other major highlights of the demand for Antibody Drug Conjugates Market include analysis, purchasing volume, prices, pricing analysis, and regulatory framework. Coverage on manufacturing structure, distribution channels, and Porter's Five Forces analysis are also incorporated in the scope to provide analysis on the demand and supply side. This is anticipated to create opportunities for the growth of the Antibody Drug Conjugates Market during the forecast period.

Seagen Inc. (previously Seattle Genetics Inc.)

Takeda Pharmaceutical Company Limited

AstraZeneca PLC

F. Hoffmann-La Roche Ltd

Pfizer Inc

ImmunoGen Inc

Gilead Sciences Inc

Daiichi Sankyo Company Limited

Market Segmentation

The Global Antibody Drug Conjugates Market Share, Demand provides the most up-to-date Pharmaceuticals industry data on the actual market situation, size, trends and future outlook. The research includes historic data from 2021 to 2023 and forecasts until 2032.

By Technology

Cleavable Linker

Non-Cleavable Linker

Linkerless

By Applications

Blood Cancer

Breast Cancer

Urothelial Cancer/Bladder Cancer

Others

Regions Covered

North America

U.S.

Canada

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Europe

U.K.

Germany

France

Spain

Italy

Russia

Nordic

Benelux

Rest of Europe

APAC

China

Korea

Japan

India

Australia

Singapore

Taiwan

South East Asia

Rest of Asia-Pacific

Middle East and Africa

UAE

Turkey

Saudi Arabia

South Africa

Egypt

Nigeria

Rest of MEA

LATAM

Brazil

Mexico

Argentina

Chile

Colombia

Rest of LATAM

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Reasons for Doing the Study:

This report is an update of an earlier (2023) Research study. Since the previous edition of this report was published, the Public Safety and Security market has continued to evolve. In particular, the overall market growth rates forecast in the previous edition now appear to have been too high, extending the time-line for the market's development. In order to give its readers, the most up-to-date and accurate assessment of future market opportunities.

If you have any special requirements, please let us know and we will offer you the report as you want.

Table of Contents:

- 1 Executive Summary
- 2 Research Scope & Segmentation
 - 2.1 Research Objectives
 - 2.2 Limitations & Assumptions
 - 2.3 Market Scope & Segmentation
 - 2.4 Currency & Pricing Considered
- 3 Market Opportunity Assessment
 - 3.1 Emerging Regions / Countries
 - 3.2 Emerging Companies
 - 3.3 Emerging Applications / End Use
- 4 Market Trends
 - 4.1 Drivers
 - 4.2 Market Warning Factors
 - 4.3 Latest Macro Economic Indicators
 - 4.4 Geopolitical Impact
 - 4.5 Technology Factors
- 5 Market Assessment
 - 5.1 Porters Five Forces Analysis
 - 5.2 Value Chain Analysis
- 6 Global Antibody Drug Conjugates Market Size Analysis
 - 6.1 By Technology
 - 6.1.1 Cleavable Linker
 - 6.1.2 Non-Cleavable Linker
 - 6.1.3 Linkerless
 - 6.2 By Applications
 - 6.2.1 Blood Cancer
 - 6.2.2 Breast Cancer
 - 6.2.3 Urothelial Cancer/Bladder Cancer
 - 6.2.4 Others
- 7 North America Market Analysis
 - 7.1 By Technology
 - 7.1.1 Cleavable Linker
 - 7.1.2 Non-Cleavable Linker
 - 7.1.3 Linkerless
 - 7.2 By Applications
 - 7.2.1 Blood Cancer

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 7.2.2 Breast Cancer
- 7.2.3 Urothelial Cancer/Bladder Cancer
- 7.2.4 Others
- 7.2 U.S.
- 7.3 Canada
- 8 Europe Market Analysis
- 8.1 By Technology
- 8.1.1 Cleavable Linker
- 8.1.2 Non-Cleavable Linker
- 8.1.3 Linkerless
- 8.2 By Applications
- 8.2.1 Blood Cancer
- 8.2.2 Breast Cancer
- 8.2.3 Urothelial Cancer/Bladder Cancer
- 8.2.4 Others
- 8.2 U.K.
- 8.3 Germany
- 8.4 France
- 8.5 Spain
- 8.6 Italy
- 8.7 Russia
- 8.8 Nordic
- 8.9 Benelux
- 8.10 Rest of Europe
- 9 APAC Market Analysis
- 9.1 By Technology
- 9.1.1 Cleavable Linker
- 9.1.2 Non-Cleavable Linker
- 9.1.3 Linkerless
- 9.2 By Applications
- 9.2.1 Blood Cancer
- 9.2.2 Breast Cancer
- 9.2.3 Urothelial Cancer/Bladder Cancer
- 9.2.4 Others
- 9.2 China
- 9.3 Korea
- 9.4 Japan
- 9.5 India
- 9.6 Australia
- 9.7 Taiwan
- 9.8 South East Asia
- 9.9 Rest of Asia-Pacific
- 10 Middle East and Africa Market Analysis
- 10.1 By Technology
- 10.1.1 Cleavable Linker
- 10.1.2 Non-Cleavable Linker
- 10.1.3 Linkerless

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 10.2 By Applications
 - 10.2.1 Blood Cancer
 - 10.2.2 Breast Cancer
 - 10.2.3 Urothelial Cancer/Bladder Cancer
 - 10.2.4 Others
- 10.2 UAE
- 10.3 Turkey
- 10.4 Saudi Arabia
- 10.5 South Africa
- 10.6 Egypt
- 10.7 Nigeria
- 10.8 Rest of MEA
- 11 LATAM Market Analysis
 - 11.1 By Technology
 - 11.1.1 Cleavable Linker
 - 11.1.2 Non-Cleavable Linker
 - 11.1.3 Linkerless
 - 11.2 By Applications
 - 11.2.1 Blood Cancer
 - 11.2.2 Breast Cancer
 - 11.2.3 Urothelial Cancer/Bladder Cancer
 - 11.2.4 Others
 - 11.2 Brazil
 - 11.3 Mexico
 - 11.4 Argentina
 - 11.5 Chile
 - 11.6 Colombia
 - 11.7 Rest of LATAM
- 12 Competitive Landscape
 - 12.1 Global Antibody Drug Conjugates Market Share By Players
 - 12.2 M & A Agreements & Collaboration Analysis
- 13 Market Players Assessment
 - 13.1 American International Industries (GIGI)
 - 13.1.1 Overview
 - 13.1.2 Business Information
 - 13.1.3 Revenue
 - 13.1.4 ASP
 - 13.1.5 Swot Analysis
 - 13.1.6 Recent Developments
 - 13.2 Takeda Pharmaceutical Company Limited
 - 13.3 AstraZeneca PLC
 - 13.4 F. Hoffmann-La Roche Ltd
 - 13.5 Pfizer Inc
 - 13.6 ImmunoGen Inc
 - 13.7 Gilead Sciences Inc
 - 13.8 Daiichi Sankyo Company Limited
- 14 Research Methodology

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 14.1 Research Data
 - 14.1.1 Secondary Data
 - 14.1.1.1 Major secondary sources
 - 14.1.1.2 Key data from secondary sources
 - 14.1.2 Primary Data
 - 14.1.2.1 Key data from primary sources
 - 14.1.2.2 Breakdown of primaries
 - 14.1.3 Secondary And Primary Research
 - 14.1.3.1 Key industry insights
- 14.2 Market Size Estimation
 - 14.2.1 Bottom-Up Approach
 - 14.2.2 Top-Down Approach
 - 14.2.3 Market Projection
- 14.3 Research Assumptions
 - 14.3.1 Assumptions
- 14.4 Limitations
- 14.5 Risk Assessment
- 15 Appendix
 - 15.1 Discussion Guide
 - 15.2 Customization Options
 - 15.3 Related Reports
- 16 Disclaimer

Antibody Drug Conjugates Market Size, Share & Trends Analysis Report By Technology (Cleavable Linker, Non-Cleavable Linker, Linkerless), By Applications (Blood Cancer, Breast Cancer, Urothelial Cancer/Bladder Cancer, Others) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2023-2031

Market Report | 2023-04-18 | 0 pages | Straits Research

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
☐	Single User License	\$4500.00
☐	Global Site License	\$5500.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

☐** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*		Phone*	
First Name*		Last Name*	
Job title*			
Company Name*		EU Vat / Tax ID / NIP number*	
Address*		City*	
Zip Code*		Country*	

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Date

2026-02-22

Signature

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com